false000172452100017245212024-06-022024-06-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 8-K
________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2024
________________________________________________________
Arcus Biosciences, Inc.
(Exact name of Registrant as Specified in Its Charter)
________________________________________________________
Delaware001-3841947-3898435
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
3928 Point Eden Way
Hayward, California
94545
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 694-6200
(Former Name or Former Address, if Changed Since Last Report)
________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, Par Value $0.0001 Per ShareRCUSThe New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 7.01 Regulation FD Disclosure.
On June 2, 2024, Arcus Biosciences, Inc. (the “Company”) presented updated information about its portfolio and development programs. An updated corporate presentation has been posted to the Investors & Media section of the Company’s website.

Item 8.01 Other Events.
The presentation included updated data from an interim analysis of the Company’s Phase 2 clinical trial EDGE-Gastric, which is evaluating domvanalimab plus zimberelimab and chemotherapy in upper gastrointestinal cancers. Specifically, the Company disclosed the following information from the interim analysis, which had a data cutoff date (DCO) of March 12, 2024:
Endpoint 
Overall*  
n=41  
PD-L1-high 
(TAP ≥5%)  
n=16 
PD-L1-low 
(TAP <5%)  
n=24   
Progression-Free Survival (PFS) 
  
 
Median in Months (95% CI) 
12.9 mos. (9.8, 13.8) 
13.8 mos. (11.3, NE) 
11.3 mos. (5.5, 13.8) 
12-month PFS Rate (95% CI) 
57.6% (41.7,73.5) 
68.8% (46.0, 91.5) 
46.8% (24.7, 68.9) 
Objective Response Rate (ORR) per RECIST v1.1 
   
Confirmed ORR (95% CI) 
58.5% (42.1, 73.7) 
 
68.8% (41.3, 89.0) 
 
50.0% (29.1, 70.9) 
Complete Response  
3 (7.3%) 
1 (6.3%) 
1 (4.2%) 
Partial Response  
21 (51.2%) 
10 (62.5%) 
11 (45.8%) 
Stable Disease  
14 (34.1%) 
5 (31.3%) 
9 (37.5%) 
Progressive Disease Confirmed  
2 (4.9%) 
0 
2 (8.3%) 
Not Evaluable** 
1 (2.4%) 
0 
1 (4.2%) 
Median Duration of Response (DOR) in Months 
12.4 mos. (9.9, NE) 
NE (11.5, NE) 
10.2 mos. (4.0, 12.4)  
*One subject with no tissue available for central PD-L1 testing. From local lab results, the subject is PD-L1 low via 22-C3 assay. This subject achieved confirmed complete response. 
** One subject has no post baseline scans 
CI: confidence interval 
NE: not evaluable 
TAP: tumor area positivity 
No unexpected safety signals were observed at the time of DCO. The domvanalimab plus zimberelimab and chemotherapy regimen was generally well tolerated and showed an overall safety profile consistent with the known safety profiles of each individual molecule to date. Infusion-related reactions were observed in 19.5% of the total subjects, and the majority were related to chemotherapy.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ARCUS BIOSCIENCES, INC.
Date: June 3, 2024By:/s/ Terry Rosen, Ph. D.
Terry Rosen, Ph.D.
Chief Executive Officer
(Principal Executive Officer)